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ABSTRACT 
Dysfunction of N-Methyl-D-aspartate receptors (NMDARS) is believed to underlie some of the 
symptoms in schizophrenia, and non-competitive NMDAR antagonists (including phencyclidine 
(PCP)) are widely used as pharmacological schizophrenia models. Furthermore, mounting 
evidence suggests that impaired γ-aminobutyric acid (GABA) neurotransmission contributes to 
the cognitive deficits in schizophrenia. Thus alterations in GABAergic interneurons have been 
observed in schizophrenia patients and animal models. Acute systemic administration of PCP 
increases levels of c-Fos in several cortical and subcortical areas, but whether such induction 
occurs in specific populations of GABAergic interneuron subtypes still remains to be established.   
We performed an immunohistochemical analysis of the PCP-induced c-Fos-immunoreactivity 
(IR) in parvalbumin and calbindin interneuron subtypes in the cortex and thalamus of rats. A 
single dose of PCP (10 mg/kg, s.c.) significantly increased total number of c-Fos-IR in: 1) the 
prelimbic, infralimbic, anterior cingulate, ventrolateral orbital, motor, somatosensory and 
retrosplenial cortices as well as the nucleus accumbens, CA1 field of hippocampus and 
mediodorsal thalamus; 2) parvalbumin-IR cells in the ventrolateral orbitofrontal and 
retrosplenial cortices and CA1 field of hippocampus; and 3) calbindin-IR cells in the motor cortex.  
Overall, our data indicate that PCP activates a wide range of cortical and subcortical brain 
regions and that a substantial part of this activation is present in GABAergic interneurons in 
certain regions. This suggests that the psychotomimetic effect of PCP may be mediated via 
GABAergic interneurons. 
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Abbreviations  
BSA, bovine serum albumin; CA1, field CA1 of the hippocampus; CB, calbindin; Cg1, cingulate 
cortex 1; CPu, caudate putamen; DAB, diaminobenzidine; GABA, γ-aminobutyric acid; GAD67, 
glutamic acid decarboxylase 67; IL, infralimbic cortex; IR, immunoreactivity; M1/M2, primary 
and secondary motor cortex; MD, mediodorsal thalamus; mPFC, medial prefrontal cortex; NAc, 
nucleus accumbens; NMDAR, N-Methyl-D-aspartate receptor; PBS, phosphate-buffered saline; 
PCP, phencyclidine; PFC, prefrontal cortex; PrL, prelimbic cortex; PV, parvalbumin; RS, 
retrosplenial cortex; S1, primary somatosensory cortex; SEM, standard error of the mean; TX, 
Triton X-100; VLO, ventrolateral orbital cortex. 
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INTRODUCTION 
Deficient glutamate-mediated excitatory neurotransmission through N-Methyl-D-aspartate 
receptors (NMDARs) is believed to underlie some of the symptoms seen in patients with 
schizophrenia (Javitt et al. 2012). The NMDAR hypofunction hypothesis of schizophrenia arose 
from studies showing that a single dose of non-competitive NMDAR antagonists (phencyclidine 
(PCP) and ketamine) evoked schizophrenia-like symptoms in healthy individuals and 
exacerbated symptoms in schizophrenia patients (Luby et al. 1959; Bakker and Amini 1961; Javitt 
and Zukin 1991; Krystal et al. 1994; Lahti et al. 1995; Malhotra et al. 1997; Adler et al. 1999). 
Non-competitive NMDAR antagonists also induce cognitive and sensory motor abnormalities in 
experimental animals (Castellani and Adams 1980; Haggerty et al. 1984; Javitt et al. 1996; 
Malhotra et al. 1997; Newcomer et al. 1999).  
Imaging studies have revealed lower metabolic activity in the prefrontal cortex (PFC), 
hippocampus, ventral striatum and thalamus in patients with schizophrenia (Morris et al. 2005), 
emphasising the involvement the cortico-limbo-thalamic circuitry in schizophrenia. The PFC is 
an important site for psychosis and cognitive problems related to schizophrenia, and it has been 
shown that acute systemic administration of ketamine or PCP rapidly increases PFC metabolic 
activity in parallel with PFC-related psychotic symptoms in healthy individuals (Vollenweider et 
al. 1997; Breier et al. 1997; Lewis, 2012). Likewise, studies in rats have shown rapid increases in 
PFC neuronal firing and expression of immediate-early genes following acute NMDAR 
antagonism (including PCP) (Suzuki et al. 2002; Gao et al. 1993, 1998). This increase in PFC 
activity has been observed to be followed by a delayed depression of activity over a 24 hours 
period followed (Gao et al. 1993, 1998), which may be relevant to the decrease in PFC activity 
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seen in schizophrenia patients. Furthermore, PFC synchronous gamma-oscillations important 
for cognitive function are impaired in schizophrenia (Cho et al. 2006; Uhlhaas and Singer, 2010; 
Minzenberg et al. 2009, 2010; Gonzalez-Burgos and Lewis, 2012). Importantly, those neurons 
mediating the psychotomimetic actions of non-competitive NMDAR antagonists are still 
unknown. Another important aspect to take into account is that also subcortical areas are 
relevant for PCP- or MK-801-mediated changes in activity and neurotransmission (Suzuki et al. 
2002; Jodo et al. 2005; Amargós-Bosch et al. 2006; López-Gil et al. 2007). Several studies point 
to the mediodorsal and centromedial thalamic nuclei, that are reciprocally connected to the PFC 
(Berendse and Groenewegen, 1991; Fuster, 2008), to be of major importance in mediating the 
effects of non-competitive NMDAR antagonists (Kargieman et al. 2007; Santana et al. 2011; Kiss 
et al. 2011; Celada et al. 2013).   
In addition to abnormal glutamatergic neurotransmission, mounting evidence suggests that 
impaired γ-aminobutyric acid (GABA)ergic neurotransmission, at least in part, mediates the 
cognitive deficits in schizophrenia (Lewis et al. 2008; Lewis et al. 2012; Gonzalez-Burgos et al. 
2015). Coordinated activity of excitatory pyramidal cells and GABAergic interneurons, in 
particular via fast-spiking parvalbumin (PV) interneurons, govern the synchronisation of gamma-
oscillations within the PFC (Gonzalez-Burgos and Lewis, 2012), and NMDARs expressed in PV 
interneurons are critical for induction of gamma-oscillations and behaviour (Sohal et al. 2009; 
Carlén et al. 2012; Belforte et al. 2010).  
Post-mortem studies in the PFC of schizophrenia patients have consistently reported reduced 
levels of the GABA synthesising enzyme, glutamic acid decarboxylase 67 (GAD67) as well as 
reduced levels of PV interneuron immunoreactivity and mRNA (Akbarian et al. 1995; Volk et al. 
2000; Eyles et al. 2002; Woo et al. 2008; Hashimoto et al. 2008). Further, PV cells exhibit 
abnormalities in several molecular features that are likely to be critical to their function as 
reviewed by Lewis (2014). Similarly, repeated administration of non-competititve NMDAR 
6 
 
antagonists (PCP, ketamine or MK-801) decreases the expression of GAD67 and PV in cortical 
GABAergic neurons in primary cortical neurons, rat and monkey (Cochran et al. 2003; Keilhoff et 
al. 2004; Rujescu et al. 2006; Behrens et al. 2007; Morrow et al. 2007) and manipulating 
GABAergic precursor neurons in the PFC can ameliorate PCP-induced cognitive changes in mice 
(Tanaka et al. 2011). Genetic deletion of the essential NMDAR1 subunit in PV interneurons in 
mice leads to disinhibition of cortical excitatory neurons, altered neuronal synchrony, and 
produces working memory deficits (Korotkova et al. 2010; Belforte et al. 2010; Carlén et al. 
2012). Changes in other mRNA levels of GABAergic interneuron subtypes such as calbindin (CB), 
neuropeptide Y, somatostatin, vasoactive intestinal peptide and cholecystokinin also have been 
observed in the PFC of schizophrenia patients (Hashimoto et al. 2003, 2008; Fung et al. 2010, 
2014).  
A range of NMDA antagonists has been used for NMDA hypofunction modelling in animals and 
humans (Gilmour et al. 2012). In this study, we chose to use the non-competitive NMDAR 
antagonist PCP, since this drug has been widely used for modelling NMDA hypofunction in 
schizophrenia and, as described above, has shown comparable effects in humans and animals. 
This potentially support translation of results between animal and human studies. It is well-
established that acute systemic administration of PCP increases levels of the immediate early 
gene (IEG) c-Fos in several areas including PFC, hippocampus, nucleus accumbens (NAc) and 
thalamic nuclei in rodents (Näkki et al. 1996; Sato et al. 1997; Griffiths et al. 1999; Habara et al. 
2001; Gotoh et al. 2002; Kargieman et al. 2007; Kargieman et al. 2008; Kalinichev et al. 2008; 
Santana et al. 2011; Castañe et al. 2015). It has been reported that PCP-induced c-Fos mRNA 
occurs in GAD67-neurons in the hippocampus, amygdala, as well as somatosensory and 
retrosplenial cortex (Santana et al. 2011). However, whether this effect occurs in subsets of 
GABAergic interneurons in cortical and subcortical areas has not been investigated.  
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In the present study, we explore whether activation of two largely non-overlapping groups of 
interneurons (Kawaguchi and Kubota, 1997; Druga, 2009) characterised by their content of the 
Ca2+-binding proteins PV and CB (DeFelipe, 1997), might be involved in the neuronal response 
to PCP. To this end, we investigated the c-Fos immunoreactivity (IR) in response to acute 
systemic PCP (10 mg/kg, s.c.) in these interneuron subtypes in cortical and thalamic regions. 
 
EXPERIMENTAL PROCEDURES 
Animals 
A total number of 17 male Wistar rats (219-239 g; around 12 weeks old) were purchased from 
Taconic Europe (Ll. Skensved, Denmark). The animals were acclimatised under standardised 
conditions with a 12/12-hr light/dark cycle and free access to food and water for seven days 
after arrival. All experiments were conducted in accordance with the Declaration of Helsinki, the 
Danish National Guide for Care and Use of Laboratory animals and the European Communities 
Council Directive of 24 November 1986 (86/609/EEC).  
 
Drug treatment 
PCP [1-(1-phenylcyclohexyl)piperidine]-hydrochloride (synthesised at the Department of 
Medicinal Chemistry, Faculty of Pharmaceutical Sciences, Copenhagen University) was dissolved 
in 0.9% saline. The rats were injected with PCP (10 mg/kg; 2 ml/kg, s.c.) or vehicle (0.9% saline; 
2 ml/kg, s.c.) and returned to their home cage for 60 min before transcardial perfusion. This 
particular dose of PCP was chosen since it has been shown to induce c-Fos in cortical and 
subcortical regions, alter discharge activity in neurons and also induce changes in c-Fos 
expression in GABAergic interneurons (Kargieman et al. 2007; Santana et al. 2011; Sato et al. 
1997; Jodo et al. 2010). 
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Transcardial perfusion and fixation 
The rats were deeply anaesthetised with a solution of pentobarbital (200 mg/ml) and 
lidocainhydrochloride (20 mg/ml) (2 ml/kg, i.p.) and subsequently perfused transcardially with 
0.1 M phosphate-buffered saline (PBS) until the blood was flushed followed by 4% 
paraformaldehyde in PBS for approximately 10 min. Brains were dissected from the skull, 
immersed in fixative overnight at 4C and submerged in 30% sucrose in PBS at 4C for 2 days. 
The brains were cut in 40 m serial coronal sections in 6 parallel series on a freezing microtome 
(Bright series 8000; Bright lnstrument, Cambridgeshire, UK), and the free-floating sections were 
stored at -20C in antifreeze solution (0.01 M NaH2PO4, 0.03 M Na2HPO4, 30% ethylenglycol, and 
30% glycerol) until use. 
 
Colorimetric immunohistochemistry 
The sections were rinsed for 3 x 10 min in PBS, incubated for 10 min in 1% H2O2 in PBS to block 
endogenous peroxidase activity and subsequently incubated for 20 min in PBS with 5% normal 
donkey serum, 1% bovine serum albumin (BSA) and 0.1% Triton X-100 (TX) to block nonspecific 
binding sites. The sections were then incubated at 4C overnight with the primary antiserum in 
PBS with 1% BSA and 0.1% TX. After incubation in primary antiserum, the sections were washed 
for 3 x 10 min in PBS with 0.1% TX (PBS-TX) and incubated for 60 min in biotin-conjugated 
secondary antibody diluted 1:1000 in PBS-TX with 1% BSA, washed for 3 x 10 min in PBS-TX and 
transferred to an avidin-biotin complex solution (#PK-6100, Vector Laboratories, Burlingame, 
CA, USA) diluted 1:500 in PBS-TX for 60 min. After washing 10 min in PBS-TX, PBS, and Tris-HCl 
(pH 7.6), the sections were incubated in either: 1) 0.1% diaminobenzidine (DAB; Sigma Aldrich, 
St. Louis, MO, USA) with 0.03% H2O2 in Tris-HCl buffer; or 2) 0.025% DAB with 0.015% H2O2, 
0.075% nickel sulphate and 5 mM imidazole in Tris-HCl buffer (DAB-nickel) for 10 min. Finally, 
9 
 
the sections were washed 3 x 10 min in PBS. For double-labelling, the procedure was repeated 
with a different primary antiserum and completed with incubation in 0.1% DAB with 0.03% H2O2 
in Tris-HCl buffer for 10 min.  
The DAB reaction (orange-brown) was applied for c-Fos-single-labelling and PV- and CB-labelling 
in double-labelling procedures. The DAB-nickel reaction was applied for c-Fos-labelling in 
double-labelling procedures producing a black colour localised to the nucleus. In order to obtain 
optimal double-labelling, c-Fos-IR in sections planned to be CB+c-Fos double-labelled were 
further silver-gold intensified using the Gallyas method (Liposits et al. 1984) prior to the 
incubation with CB antibody. The sections were mounted on gelatinized glass slides, dried, and 
coverslipped in Pertex. 
 
Antibodies 
Primary antisera used and their concentrations were as follows: polyclonal antiserum against c-
Fos (1:8000 for single staining and 1:16000 for double staining), generated in a rabbit with a 
peptide corresponding to amino acids 2-17 of the rat c-Fos protein in our laboratory and 
previously characterised (Mikkelsen et al. 1998), polyclonal rabbit antibody against PV (1:6000, 
#PC255L; Merck Millipore, Darmstadt, Germany) and monoclonal mouse anti-CB-D-28K 
antibody (1:20000, #C9848; Sigma Aldrich, St. Louis, MO, USA). 
Biotin-conjugated secondary antibodies were raised in donkey, from Jackson Laboratories (Ben 
Harbor, ME) and used in a 1:1000 dilution. 
 
Regions of interest 
Prelimbic cortex (PrL), infralimbic cortex (IL), cingulate cortex 1 (Cg1), primary and secondary 
motor cortex (M1/M2), primary somatosensory cortex (S1) and ventrolateral orbital cortex 
(VLO) were analysed in sections within 3.72 mm to 2.52 mm from bregma (figure 1, left). Nucleus 
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accumbens shell (NAc shell) and core (NAc core) as well as caudate putamen (CPu) were 
analysed in sections within 2.16 mm to 1.32 mm from bregma (figure 1, middle). Retrosplenial 
cortex (RS), field CA1 of the hippocampus (CA1) and mediodorsal thalamus (MD) were analysed 
in sections within -2.92 mm to -3.24 mm from bregma (figure 1, right) (according to Paxinos and 
Watson (5th ed.) 2004). The counting frames were placed in similar localisations in each region 
for each neuronal marker. However, there were some differences in the placement of the 
M1/M2 and S1 counting frames. PV+c-Fos double-stained sections were counted in cortical 
layers II-V of M1/M2 and S1 – corresponding to the single c-Fos countings (figure 1). In CB+c-Fos 
double-stained sections, layers III-VI were counted in M1/M2 and S1. Hence, CB-IR cells are a 
very heterogeneous group of cells including both GABAergic and non-GABAergic cells, which can 
be distinguished from each other by the IR intensity and localisation. GABAergic CB-IR cells are 
intensely labelled and localised to cortical layer II-VI, whereas non-GABAergic CB-IR cells are 
weakly stained and mainly localised in cortical layers II and III (Gonchar and Burkhalter, 1997). 
Thus the counting frames for CB+c-Fos-labelled sections were placed to avoid counting the 
weakly stained CB-IR cells. CB-IR cells in NAc shell and MD are not included in the analysis, since 
these cells have been shown not to be GABAergic neurons and were therefore not included in 
the analysis (Hendry and Jones, 1989; Sadikot and Sasseville, 1997). 
 
Semi-quantitative assessment of immunoreactive neurons 
All countings were done by an observer blind to the treatment regimens, and the cells were 
independently recounted by a second observer. The number of positive cells for each region was 
averaged from both hemispheres on two adjacent sections. In order to count c-Fos-IR in single-
stained sections, 100x magnified images (1.027 mm x 0.770 mm) of the area of interest were 
obtained under bright field illumination in a Zeiss Imager.Z1 microscope and c-Fos-IR cells were 
counted with ImageJ 1.46r software by an automated procedure counting particles of 
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appropriate size with a specific threshold held constant through all the animals in the 
experiment. The number of PV-IR and CB-IR cells and cells, which were also c-Fos-IR, were 
counted manually under bright field illumination in a Zeiss Imager.Z1 microscope (400x 
magnification) using NewCast software (Visiopharm, Hoersholm, DK) to frame the regions of 
interest.  
The data from single-c-Fos-IR countings are presented as c-Fos-IR per area, whereas the data 
from double-stainings are presented as the relative numbers of PV-IR and CB-IR neurons, 
respectively, which were also c-Fos-IR.  
In order to obtain a meaningful relative number of c-Fos-IR interneurons, the inclusion criterion 
number was 15 total PV-IR or CB-IR cells per animal within a particular region. Regions where 
more than 80% of the animals had less than 15 interneurons were excluded from analysis and 
noted as not detectable (N.D.; table 1 and 2). See table 1 for numbers of counted PV-IR and CB-
IR cells in all regions of interest. 
 
Statistical Analysis 
D'Agostino & Pearson normality test was performed and c-Fos-IR and PV+c-Fos-IR data were 
square-root-transformed for obtaining normal distribution. Transformed data (c-Fos-IR and 
PV+c-Fos-IR data) and non-transformed data (CB+c-Fos+IR data) were analysed using multiple 
unpaired t-tests (with and without Welch’s correction, respectively) corrected for multiple 
comparisons with Holm-Sidak post hoc test (obtaining adjusted P-values) (see table 2). Statistical 
tests and graphs (figures 3, 5, 6, 8 and table 2) were generated using GraphPad Prism version 
7.0 for Windows (GraphPad Software, San Diego, USA). All data are presented as mean ± 
standard error of the mean (SEM) and P-values less than 0.05 were considered statistically 
signiﬁcant.  
 
12 
 
RESULTS 
PCP induces c-Fos-IR in cortical areas and MD. 
The number of c-Fos-IR cells per area was counted in sections from rats treated with vehicle 
(saline; N=8) or acute PCP (10 mg/kg; N=9) (figure 2) and Holm-Sidak-corrected multiple t-tests 
on transformed data were performed to compare vehicle and PCP treated groups. This analysis 
showed that PCP significantly increased c-Fos-IR in the following regions: PrL (P<0.05, t-
ratio=3.02, df=15), IL (P<0.05, t-ratio=3.77, df=15), Cg1 (P<0.05, t-ratio=3.24, df=15), VLO 
(P<0.001, t-ratio=11.33, df=15), M1/M2 (P<0.001, t-ratio=7.77, df=15), S1 (P<0.05, t-ratio=6.05, 
df=15), RS (P<0.001, t-ratio=5.10, df=15), NAc core (P<0.05, t-ratio=2.84, df=15), MD (P<0.001, 
t-ratio=5.65, df=15), CA1 (P<0.05, t-ratio=2.191, df=15), but not in , NAc shell and CPu (see table 
2 and figure 3). 
 
PCP induces c-Fos-IR in PV-IR cells in the VLO, RS and CA1. 
The number of PV-IR cells and PV+c-Fos-IR cells were counted in sections from the same animals 
as above (figure 4). The relative number of PV-IR cells co-labelled with nuclear c-Fos-IR, was 
calculated and Holm-Sidak-corrected multiple t-tests were performed on transformed data to 
compare the groups (see table 2 and figure 5). This analysis showed that PCP significantly 
induced c-Fos-IR in PV-IR cells in the VLO (P<0.001, t-ratio=7.49, df=15), RS (P<0.001, t-
ratio=5.84, df=15) and CA1 (P<0.001, t-ratio=5.90, df=15). These effects were not due to 
differences in numbers of PV-IR cells between treatment groups, since no PCP-dependent 
differences in PV cells numbers were found in these regions (data not shown). No significant 
PCP-induced effects were found in the PrL, IL, Cg1, M1/M2, S1 and CPu. Very low numbers of 
PV-IR cells were detected in NAc core and shell and MD, and therefore these areas were not 
analysed according to selection criteria.  
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PCP induces c-Fos-IR in CB-IR cells in M1/M2. 
The number of CB-IR cells and CB+c-Fos-IR cells were counted in sections from the same animals 
as above (see table 1) (figure 6.A). The relative number of CB-IR cells, which were also c-Fos-IR, 
was calculated and Holm-Sidak-corrected multiple t-tests were performed to compare the 
groups (see table 2 and figure 6. A,B). This analysis showed that among the regions examined 
PCP only induced c-Fos-IR in CB-IR cells in the M1/M2 (P<0.001, t-ratio=5.19, df=15). In CB-IR 
cells in the PrL, IL, Cg1, S1 and VLO c-Fos-IR were not increased by PCP administration. No or an 
insufficient number of CB-IR cells were detected in NAc core, CPu, RS and CA1.  
 
DISCUSSION 
The present study demonstrates by immunohistochemical analysis that acute PCP stimulates 
induction of c-Fos in cortical and limbic areas as well as the MD and that a part of this increase 
is due to activation of the PV interneuron subtype. 
 
PCP-induced c-Fos-IR in the PFC and MD 
We show that acute PCP treatment induces widespread c-Fos-IR in most brain regions examined 
including cortical, limbic and thalamic regions. More specifically, PCP-induced c-Fos-IR was 
observed all PFC subregions examined (PrL, IL, Cg1 and VLO) as well as motor cortex, S1, RS, CA1, 
NAc core and MD. Overall, this observation agrees with previous studies showing that acute PCP 
administration at the same dose as used here induced elevations in c-Fos mRNA in the PFC, RS, 
S1, motor cortex and MD (Kargieman et al. 2007; Santana et al. 2011), but not CA1 (Santana et 
al. 2011). Studies using other doses of PCP or other non-competitive NMDAR antagonists also 
report c-Fos mRNA or protein elevations in these areas (Habara et al. 2001 (5 mg/kg PCP); Gotoh 
et al. 2002 (7.5 mg/kg PCP); De Leonibus et al. 2002 (MK-801); Väisänen et al. 2004 (MK-801); 
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Imre et al. 2006 (ketamine)). Electrophysiological studies further report that acute non-
competitive NMDAR antagonists (MK-801 and PCP) affects the firing activity in PFC and thalamic 
neurons in vivo (Jackson et al. 2004; Jodo et al. 2005; Kargieman et al. 2007; Homayoun and 
Moghaddam, 2007; Santana et al. 2011).  
We find significant increases in PCP-induced c-Fos-IR in the NAc core, and not in other striatal 
regions examined. This is supported by previous studies (Habara et al. 2001), but this finding is 
not consistent across all studies using NMDA antagonists (Gao et al. 1998 (NAc overall); De 
Leonibus et al. 2002 (NAc core)). We also find that PCP induces c-Fos-IR in the CA1, which has 
not previously been found in studies with similar or lower PCP doses (Näkki et al. 1996; Gotoh 
et al. 2002 Santana et al. 2011), but is in line with previous studies using stronger PCP doses or 
other NMDA antagonists (Näkki et al. 1996; Väisänen et al. 2004; Imre et al. 2006) supporting 
this region to be involved in mechanisms underlying NMDA hypofunction. 
Interestingly, in addition to what has previously been reported, we find that PCP strongly 
activates c-Fos in the VLO specifically, which is a region highly functionally coupled to the mPFC 
through robust reciprocal projections. Our results suggest a dissociable PCP-induced activation 
of the mPFC versus the VLO, since the VLO is more strongly affected by PCP treatment. This, 
together with the differences in the c-Fos-IR basal levels of mPFC and VLO, indicate that different 
mechanisms might contribute to PCP-induced c-Fos-IR in the mPFC versus the VLO, which is 
likely, given the functional dissociation of these two PFC subregions (Kolb et al. 2004). 
   
Several studies have shown that the PFC and MD are the predominant sites mediating the 
actions of non-competitive NMDAR antagonists, including changes in neurotransmission and 
behaviour (Amargós-Bosch et al. 2006; López-Gil et al. 2007; Kargieman et al. 2007; Zhang et al. 
2009, 2012; Santana et al. 2011; Kiss et al. 2011; López Hill and Scorza 2012). Furthermore, it 
has been proposed that PCP acts on the cortico-thalamo-cortical circuit involving the PFC, RS 
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and thalamus (Celada et al. 2013). Our observations support the involvement of the PFC, RS and 
MD in the actions of NMDAR antagonism. Due to the reciprocal connectivity of these areas, one 
would expect activity of these regions to be coupled. There are, however, some differences in 
the degree of PCP-induced c-Fos-IR in these regions - suggesting that different mechanisms 
might contribute to the effects of PCP, or that the primary PCP-mediated activation is at an 
afferent site that projects stronger to the VLO and RS than the mPFC. Studies have shown that 
whereas systemic administration of non-competitive NMDAR antagonists leads to PFC and MD 
hyperactivity, locally injected antagonists in the PFC has no effect on the activity of PFC neurons 
(Suzuki et al. 2002; Jodo et al. 2005; Kiss et al. 2011) suggesting excitatory inputs to the PFC to 
be involved in the actions of non-competitive NMDAR antagonists. Further, local MK-801 
administration into the MD produces effects similar to systemically injected MK-801 (Kiss et al. 
2011) indicating that non-competitive NMDAR antagonists act on circuit level at thalamic areas.  
Since we observe increased c-Fos-IR in the motor cortex and S1 by PCP treatment, these areas 
may also contribute to the PCP-induced increased inputs to the PFC. 
Since 70–80% of neocortical neurons are excitatory pyramidal neurons and 20–30% are 
interneurons (Markram et al. 2004), these overall increases in c-Fos-IR observed in the present 
study are likely to represent mainly excitatory activity of pyramidal neurons, but a fraction of 
the activated neurons may also include GABAergic interneurons. 
 
PCP-induced c-Fos-IR in GABAergic interneurons 
We show that, as opposed to CB-IR neurons, the c-Fos-IR in PV-IR neurons is affected by PCP 
treatment in several regions, supporting a specific role for PV interneurons in the effects of 
NMDAR antagonism.  
The PV positive subgroup of interneurons has received much attention in relation to its 
involvement in schizophrenia (Gonzalez-Burgos and Lewis, 2012). In rat cortex, PV is expressed 
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in around 50% of GABAergic interneurons (Gonchar and Burkhalter, 1997). Furthermore, PV cells 
innervate both pyramidal neurons and other interneurons (Druga, 2009). Thus PV cells play a 
central role in coordinating the activity of excitatory pyramidal cells and GABAergic interneurons 
governing the synchronisation of cortical gamma-oscillations (Gonzalez-Burgos and Lewis, 
2012), and it has been shown that the induction of gamma-oscillations is dependent on NMDARs 
expressed in PV interneurons (Sohal et al. 2009; Carlén et al. 2012). Although the mPFC contains 
the PV neurons generating and regulating gamma-oscillations and is probably the site important 
in schizophrenia patients (Beasley and Reynolds, 1997; Danos et al. 1998; Zhang and Reynolds 
2002; Cho et al. 2006; Uhlhaas and Singer 2010; Minzenberg et al. 2009, 2010) and animal 
models (Cochran et al. 2003; McKibben et al. 2010; Thomsen et al. 2010), we found no PCP-
induced c-Fos-IR in PV-IR cells in the mPFC areas. Consistently, a previous study found no 
increase in c-Fos mRNA in GABAergic neurons in the mPFC (Santana et al. 2011). It is likely that 
the lack of increased activity in the PV interneurons in the mPFC may be due to PCP directly 
blocking the NMDARs in these PV cells, which may contribute to the overall increased c-Fos-IR 
in the mPFC, as described above, due to lack of control by local PV interneurons. Interestingly, 
in contrast to the mPFC, we observe PCP-induced c-Fos-IR in PV cells in the VLO, which is not 
only closely interconnected with the mPFC, but also to the MD (Price 2007). Thus over-excited 
PV cells in the VLO may lead to altered excitatory inputs to the mPFC and MD and hence 
contribute to altered activity in excitatory neurons in these regions. It is relevant to note that 
the c-Fos-IR basal level of PV cells in the VLO is low compared to the mPFC subregions (PrL, IL 
and Cg1) and that the number of PCP-induced c-Fos-IR cells in the VLO is actually at the level of 
the basal levels of these mPFC subregions. This indicates that GABAergic neurotransmission at 
rest in the VLO is different from that in the mPFC. Based on this observation, it would be 
interesting to further investigate differences in the GABAergic neurotransmission in the mPFC 
versus the orbitofrontal cortex.  
17 
 
In the present study, we also observe that PCP highly induces c-Fos-IR in PV-IR cells localised in 
the RS and CA1. Both regions are thought to be affected in schizophrenia (Morris et al. 2005; 
Bluhm et al. 2009) and connected to the PFC (Van Groen and Wyss, 2003; Price, 2007). Previous 
studies have shown that PCP administration increases the c-Fos mRNA expression in both 
glutamatergic and GAD67 positive neurons in the RS and in GAD67 positive neurons in the CA1 
(Kargieman et al. 2007; Santana et al. 2011). This corresponds to our observations, where we 
see PCP highly inducing c-Fos-IR overall and in PV-IR neurons in the RS, whereas PCP moderately 
induces overall c-Fos-IR, but strongly induces c-Fos-IR in PV-IR cells, in the CA1, which is a region 
that innervates the RS (Cenquizca and Swanson, 2007).  
Celada et al. (2013) has proposed that PCP acts on GABAergic neurons in the reticular nucleus 
of thalamus, which in turn disinhibits relay neurons of thalamic nuclei. These relay neurons 
would subsequently increase the excitatory inputs to both GABAergic and glutamatergic cells in 
S1 and RS and thus potentially exert dual inﬂuence on PFC pyramidal cells by direct excitation 
and indirect inhibition via local GABAergic interneurons (Celada et al. 2013). We find PCP-
induced c-Fos-IR in neurons overall in the S1 and RS and in GABAergic PV neurons in the RS, but 
not the S1 (as reported in (Santana et al. 2011)). This may either be due to lack of effect of PCP 
in the S1 or to differences in the cortical layers examined, since we examined the cortical layers 
II-V as opposed to exclusively the inner layers (IV-VI) (Santana et al. 2011).  
 
Overall, these findings show that PCP increases the activity of PV-IR neurons in areas directly 
connected to the mPFC, but not the mPFC itself, which may support that PCP mediates its effect 
indirectly via subcortical projections to the mPFC (Jodo, 2013; Celada et al. 2013). However, it is 
likely that the lack of increased activity in the mPFC PV interneurons may be due to PCP directly 
blocking the NMDARs in these PV cells, since PCP has been shown to act directly on GABAergic 
interneurons in the PFC (Homayoun and Moghaddam 2007). Together with the increased 
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activity in the input systems, including in particular the VLO as well as the MD, S1 and RS, this 
may contribute to the increased mPFC network activity, since it is not compensated by PV 
interneuron-mediated inhibition. Thus this results in a disturbance of the excitatory-inhibitory 
balance as proposed to be relevant in the NMDA hypofunction model of schizophrenia (Kehrer 
et al. 2008). In theory this can also be the case for other regions, e.g. the motor cortex and S1, 
where we observe PCP-induced c-Fos-IR overall, but lack of activity in the PV neurons. However, 
conclusions regarding these regions will be more speculative, since these have not been 
investigated as intensively as the PFC in regard to the NMDA hypofunction model. 
 
Here we investigated the effects of acute blocking of NMDARs on c-Fos expression. Despite the 
relevance of investigating acute effects, we acknowledge the importance of investigating the 
effects of sub-chronic PCP administration on regional c-Fos expression, since this is a model 
widely used for mimicking a range of schizophrenia-related symptoms (Meltzer et al. 2011, 
2013). It is also important to investigate other immediate early genes suggested to be relevant 
to schizophrenia such as activity-regulated cytoskeleton-associated protein, Homer 1 and 
deltaFosB (Purcell et al. 2014; Iasevoli et al. 2014; Dietz et al. 2014).   
 
Conclusion 
The NMDA hypofunction model may not elucidate the highly complex set of mechanisms leading 
to schizophrenia in humans, but it can help our understanding of the mechanisms leading to 
acutely induced schizophrenia-like states in humans. The present study shows that PCP induces 
a diverse c-Fos-IR pattern in specific GABAergic interneuron subtypes in cortical and subcortical 
brain areas. PV-IR neurons that are thought to be highly implicated in schizophrenia (Gonzalez-
Burgos and Lewis, 2012) show increased PCP-induced c-Fos-IR in the orbitofrontal cortex and 
limbic regions, but not in the mPFC. Overall, our data indicate that PCP exerts a profound 
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disruption of cortico-limbo-thalamic networks partly by altering the activity of specific 
GABAergic interneuron subtypes which opens the possibility that the psychotomimetic effects 
of PCP may reside in its effect on GABAergic interneurons. This supports the hypothesis that 
GABAergic interneurons are prime targets in NMDAR antagonism. 
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FIGURE LEGENDS 
Figure 1. Schematic diagrams of representative coronal brain sections selected for 
immunohistochemical analysis. Frames delineate the areas analysed within each region of 
interest:  (1) prelimbic prefrontal cortex (PrL); (2) infralimbic prefrontal cortex (IL); (3) cingulate 
cortex 1 (Cg1); (4) primary and secondary motor cortex (M1/M2); (5) primary somatosensory 
cortex (S1); (6) ventrolateral orbitofrontal cortex (VLO); (7) nucleus accumbens shell (NAc shell); 
(8) nucleus accumbens core (NAc core); (9) caudate putamen (CPu); (10) retrosplenial cortex 
(RS); (11) field CA1 of the hippocampus (CA1); (12) mediodorsal thalamus (MD). Left diagram: 
3.00 mm from bregma; middle diagram: 1.80 mm from bregma; right diagram: -3.36 mm from 
bregma. (Diagrams modified from Paxinos and Watson 5th ed. 2004). 
 
Figure 2. c-Fos localisation after PCP or vehicle administration. Representative micrographs 
(100x magnification; scale bar, 250 m) of sections labelled with c-Fos antibody (dark nuclei) in 
different brain regions of rats treated with vehicle (saline) or PCP (10 mg/kg). The black masks 
in images of RS, MD and CA1 outline the areas analysed. (Note that RS, MD and CA1 were 
reacted with DAB-nickel, whereas all other regions were reacted with DAB).  
 
Figure 3. Bar graph showing c-Fos-IR per area in different brain regions of rats treated with 
vehicle (saline) (N=8) or PCP (10 mg/kg) (N=9). *P<0.05 and *** P<0.001. (Note that RS, MD and 
CA1 were reacted with DAB-nickel, whereas all other regions were reacted with DAB resulting 
in differences in staining-intensity and hence not directly comparable c-Fos-IR levels).  
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Figure 4. PV and c-Fos colocalisation after PCP or vehicle administration. Representative 
micrographs (400x magnification; scale bar, 65 m) of sections double-labelled with PV (brown) 
and c-Fos (dark nuclei) antibodies in different brain regions of rats treated with vehicle (saline) 
or PCP (10 mg/kg). Black arrows indicate double-labelled cells.  
 
Figure 5. Bar graph showing the relative number of PV-IR cells, which were also c-Fos-IR, in 
different brain regions of rats treated with vehicle (saline) (N=8) or PCP (10 mg/kg) (N=9). *** 
P<0.001. N.D., not detectable. 
 
Figure 6. CB and c-Fos colocalisation after PCP or vehicle administration. (A) Representative 
micrographs (400x magnification; scale bar, 65 m) of sections double-labelled with CB (brown) 
and c-Fos (dark nuclei) antibodies in different brain regions of rats treated with vehicle (saline) 
or PCP (10 mg/kg). (B) Bar graph showing the relative number of CB-IR cells, which were also c-
Fos-IR, in different brain regions of rats treated with vehicle (saline) (N=8) or PCP (10 mg/kg) 
(N=9). *** P<0.001. N.D., not detectable. 
